None
Quote | INmune Bio Inc. (NYSE:INMB)
Last: | $ |
---|---|
Change Percent: | 3.27% |
Open: | $5.00 |
Close: | $5.05 |
High: | $5.30 |
Low: | $4.8001 |
Volume: | 22,030 |
Last Trade Date Time: | 02/12/2020 04:40:27 pm |
News | INmune Bio Inc. (NYSE:INMB)
2024-05-01 16:50:15 ET More on INmune Bio INmune Bio: An Opportunity In The Freefall (Rating Upgrade) INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript INmune Bio provides update on Alzheimer's candidate XPro INmune Bio rises 2%, on $4.5M direct offeri...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Message Board Posts | INmune Bio Inc. (NYSE:INMB)
Subject | By | Source | When |
---|---|---|---|
Did the trial in ovarian ever start? | jondoeuk | investorshub | 04/11/2023 7:45:58 PM |
Don't need to convince us. We are fully | derkampfer | investorshub | 04/09/2023 1:10:54 PM |
Sure, it is early days in patients, but | jondoeuk | investorshub | 04/06/2023 11:10:04 PM |
blocked | dennisdave | investorshub | 12/01/2022 3:05:20 PM |
INMB chart....finally a reversal? | conix | investorshub | 03/30/2022 1:11:42 AM |
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an up...
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, continues to advance its Nat...